The ability of anti-VEGF therapy to stop fluid accumulation in the macula after neovascularization secondary to age-related macular degeneration (AMD) has been proven in clinical studies, but no clear answers are yet available on the appropriate endpoint of therapy. Despite success in treating leakage from new blood vessels, anti-VEGF therapy...

Radiation therapy, when used to treat patients requiring chronic anti-VEGF therapy, may reduce the burden of treatment for neovascular age-related macular degeneration (AMD). According to results from a study presented by Dr Pravin Dugel at the joint meeting of the American Academy of Ophthalmology and Pan-American Association of Ophthalmology,...

Interim analysis of a pilot study of combination anti-VEGF therapy and externally delivered radiation for the treatment of age-related macular degeneration has shown encouraging visual acuity and anatomical outcomes and no safety signals, according to a speaker at the Retina 2010 meeting. The IRay system (Oraya Therapeutics) delivers radiation...

Oraya Therapeutics announced that enrollment is now underway for a masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with...

The use of epimacular brachytherapy (radiation) combined with Avaastin (bevacizumab) appears safe for treatment of neovascular age-related macular degeneration and reduces the dosing burden of anti-VEGF therapy. After 2 years of follow-up in 34 patients treated with strontium 90 and Avastin in a phase 2 study, 80% of patients who had cataract...

A small 1-year prospective study of Avastin plus epiretinal brachytherapy combination therapy for the treatment of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) reports favorable safety and efficacy results. "Radiation has been used for some time in the treatment of ocular neovascularization....

Promising 1-year safety and efficacy results of intraocular epiretinal beta radiation therapy of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) are reported by a new research study. "Radiation has been used for some time in the treatment of ocular neovascularization. It is an interesting option...

Many physicians are awaiting the results of a trial comparing two leading anti-VEGF agents in the treatment of neovascular age-related macular degeneration (wet AMD). But because study results will not be known for several years, they continue to practice with varying therapies, regimens and doses, trying to find an ideal treatment for their...

NeoVista, Inc. made public yesterday 18-month data from the company's Phase II feasibility study examining its novel epiretinal brachytherapy for treatment of the wet form of age-related macular degeneration (AMD) at the 41st Scientific Meeting of the Retina Society. The long-term data from the study, which was initiated to test the safety...

A new method of selective epiretinal brachytherapy combined with anti-VEGF therapy may be a promising treatment approach for patients with neovascular age-related macular degeneration. "Radiation has been used for some time in the treatment of ocular neovascularization. It is an interesting option because it attacks several of the important...